세계의 대사증후군 시장 보고서(2025년)

Metabolic Syndrome Global Market Report 2025

US $ 4,490 ￦ 6,219,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,990,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,761,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

대사증후군 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 연평균 7.4%의 성장률(CAGR)로 1,206억 9,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안의 성장은 일상 생활에서의 스트레스 수준 증가, 건강 관리에 대한 인식 증가, 고급 진단 도구에 대한 수요 증가, 대사성 질환에 대한 진단 검사 수 증가, 의료 보험 적용 범위 확대 등에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 의료 기술 발전, 대사 건강 모니터링 강화, 인공지능의 통합, 디지털 건강 도구의 채택, 스마트한 섭취형 정제 개발 등을 꼽을 수 있습니다.

생활습관병의 유병률 증가는 대사 검사 시장의 성장을 가속할 것으로 예측됩니다. 생활습관병은 유전적 요인이나 감염 요인이 아닌 주로 건강에 해로운 습관이나 행동에 의해 유발되는 건강 상태를 말합니다. 대표적인 예로는 비만, 암, 2형 당뇨병, 골다공증, 정신질환 등이 있습니다. 이러한 질병의 발병률 증가는 좌식 생활, 건강에 해로운 식습관, 스트레스 수준 증가, 담배와 알코올의 보급으로 인해 발생합니다. 대사 증후군은 만성 염증, 대사 기능 저하, 심혈관 위험 증가를 촉진하고 생활습관병의 악화에 중요한 역할을 합니다. 예를 들어, 영국 정부 기관인 National Health Service England에 따르면, 비당뇨병성 고혈당(당뇨병 예비군)으로 진단받은 사람의 수는 2022년 3,065,825명에서 2023년 3,615,330명으로 18% 증가할 것으로 예상하고 있습니다. 이에 따라 생활습관병 유병률 증가가 대사 검사 시장 확대에 박차를 가하고 있습니다.

대사증후군 시장의 주요 기업들은 질병 관리, 치료 및 예방을 개선하기 위해 임상적으로 입증된 프로바이오틱스 솔루션과 같은 기술 혁신에 초점을 맞추었습니다. 임상적으로 입증된 프로바이오틱스 솔루션은 엄격한 임상시험을 통해 건강상의 이점과 안전성을 검증하고 있습니다. 예를 들어, 2024년 10월, 미국에 본사를 둔 임상적으로 입증된 생물학적 제제 제조업체인 Probi USA는 락토바실러스 플란타럼 299v 균주(LP299V 균주)와 락토바실러스 파라카세이 바실러스 파라카세이 8700,2 균주(L. Paracasei 8700,2 균주)를 결합한 프로바이오틱스를 출시했습니다. LP299V는 콜레스테롤 수치, 염증, 혈관 기능을 개선해 심혈관 건강을 돕고, 230여 편의 논문과 8건의 임상시험을 통해 그 효능을 입증한 바 있으며, L. 파라카세이 8700, 2(L. Paracasei 8700, 2)는 L. 파라카세이 2(L. Paracasei 2) 2(L.Paracasei 8700,2)는 30편 이상의 논문을 통해 혈압 조절, 콜레스테롤 관리, 체중 조절에 도움을 줍니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나바이러스 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 대사증후군 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 대사증후군 시장 : 성장률 분석
• 세계의 대사증후군 시장 실적 : 규모와 성장, 2019-2024
• 세계의 대사증후군 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 대사증후군 전체 시장(TAM)

제6장 시장 세분화

• 세계의 대사증후군 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 유형 1 대사증후군
• 유형 2 대사증후군
• 유형 3 대사증후군
• 세계의 대사증후군 시장 : 리스크 요인별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 비만
• 인슐린 저항성
• 고혈압
• 고콜레스테롤
• 세계의 대사증후군 시장 : 치료별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 약제
• 라이프스타일 변화
• 기타 치료법
• 세계의 대사증후군 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 비경구
• 기타 투여 경로
• 세계의 대사증후군 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원
• 홈케어
• 전문센터
• 기타 최종사용자
• 세계의 대사증후군 시장 : 1형 대사증후군 세분화(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 인슐린 저항성 증후군
• 복부 비만 후군
• 고혈당 증후군
• 세계의 대사증후군 시장 : 2형 대사증후군 세분화(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 고혈압 증후군
• 이상지질혈증 증후군
• 저HDL 콜레스테롤 증후군
• 세계의 대사증후군 시장, 3형 대사증후군별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 동맥 경화성 심혈관질환 증후군
• 비알코올성 지방성 간질환 증후군
• 만성 염증 증후군

제7장 지역별/국가별 분석

• 세계의 대사증후군 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 대사증후군 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 대사증후군 시장 : 경쟁 구도
• 대사증후군 시장 : 기업 개요
  • Novo Nordisk A/S : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Sanofi S.A. : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Boehringer Ingelheim GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Eli Lilly and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Amgen Inc.
• AstraZeneca PLC
• Adocia
• Biocon Ltd.
• Bristol-Myers Squibb Company
• Cipla Limited
• Herbalife International of America Inc.
• Abbott Laboratories
• Shaklee Corporation
• Johnson & Johnson Private Limited
• Medtronic plc
• Apollo
• WW International Inc.
• Jenny Craig
• DSM

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 대사증후군 시장(2029년) : 새로운 기회를 제공하는 국가
• 대사증후군 시장(2029년) : 새로운 기회를 제공하는 부문
• 대사증후군 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Metabolic syndrome is a collection of risk factors that increase the likelihood of developing heart disease, stroke, and type 2 diabetes. It is commonly associated with poor lifestyle choices, including unhealthy eating habits, lack of physical activity, and obesity. Treatment primarily focuses on lifestyle modifications, such as dietary changes, regular exercise, and medications to manage specific risk factors.

The primary types of metabolic syndrome include type 1, type 2, and type 3 metabolic syndrome. Type 1 metabolic syndrome is a rare metabolic disorder, often linked to genetic or autoimmune factors, that contributes to insulin resistance, obesity, and other cardiovascular risks. Treatments target various risk factors, including obesity, insulin resistance, high blood pressure, and high cholesterol. Management options include medications, lifestyle modifications, and other therapeutic approaches. Treatment is administered through oral, parenteral, and other routes and is utilized by various end users, such as hospitals, home care, and specialty centers.

The metabolic syndrome market research report is one of a series of new reports from The Business Research Company that provides metabolic syndrome market statistics, including metabolic syndrome industry global market size, regional shares, competitors with a metabolic syndrome market share, detailed metabolic syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the metabolic syndrome industry. This metabolic syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metabolic syndrome market size has grown strongly in recent years. It will grow from $84.03 billion in 2024 to $90.60 billion in 2025at a compound annual growth rate (CAGR) of 7.8%. The growth during the historic period can be attributed to sedentary work environments, the expansion of nutraceuticals and functional foods, rising consumer demand for natural products, increasing clinical research and trials, and advancements in healthcare digitalization.

The metabolic syndrome market size is expected to see strong growth in the next few years. It will grow to $120.69 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth during the forecast period can be attributed to rising stress levels in daily life, increasing healthcare awareness, growing demand for advanced diagnostic tools, a higher number of diagnostic tests for metabolic conditions, and expanding healthcare insurance coverage. Key trends in the forecast period include advancements in medical technology, enhanced metabolic health monitoring, the integration of artificial intelligence, the adoption of digital health tools, and the development of smart ingestible pills.

The rising prevalence of lifestyle diseases is expected to drive growth in the metabolic testing market. Lifestyle diseases are health conditions primarily caused by unhealthy habits and behaviors rather than genetic or infectious factors. Common examples include obesity, cancer, type 2 diabetes, osteoporosis, and mental health disorders. The increasing incidence of these conditions is attributed to sedentary lifestyles, unhealthy diets, rising stress levels, and the widespread use of tobacco and alcohol. Metabolic syndrome plays a crucial role in worsening lifestyle diseases by promoting chronic inflammation, impaired metabolic functions, and heightened cardiovascular risks. For example, according to the National Health Service England, a UK-based government department, the number of individuals diagnosed with non-diabetic hyperglycemia (pre-diabetes) increased by 18% from 3,065,825 cases in 2022 to 3,615,330 cases in 2023. As a result, the growing prevalence of lifestyle diseases is fueling the expansion of the metabolic testing market.

Leading companies in the metabolic syndrome market are focusing on technological innovations, such as clinically supported probiotic solutions, to improve disease management, treatment, and prevention. Clinically supported probiotic solutions undergo rigorous clinical testing to validate their health benefits and safety. For instance, in October 2024, Probi USA, a US-based manufacturer of clinically proven biotics, launched "Metabolic Health," a probiotic product combining two strains that include Lactiplantibacillus plantarum 299v (LP299V) and Lacticaseibacillus paracasei 8700,2 (L. Paracasei 8700,2). LP299V supports cardiovascular health by improving cholesterol levels, inflammation, and blood vessel function, with over 230 publications and eight clinical trials backing its efficacy. L. Paracasei 8700,2, supported by over 30 publications, aids in blood pressure regulation, cholesterol management, and weight control.

In August 2023, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Inversago Pharma for an undisclosed amount. This acquisition strengthens Novo Nordisk's clinical pipeline for obesity and related disorders by investigating Inversago's lead drug, INV-202, as a potential treatment for obesity and its associated complications. Inversago Pharma Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in therapies for metabolic and fibrotic diseases.

Major players in the metabolic syndrome market are Novo Nordisk A/S, Sanofi S.A., Boehringer Ingelheim GmbH, Eli Lilly and Company, Merck KGaA, Amgen Inc., AstraZeneca PLC, Adocia, Biocon Ltd., Bristol-Myers Squibb Company, Cipla Limited, Herbalife International of America Inc., Abbott Laboratories, Shaklee Corporation, Johnson & Johnson Private Limited, Medtronic plc, Apollo, WW International Inc., Jenny Craig, DSM, Takeda Pharmaceutical Company Limited, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche AG, Merck & Co. Inc.

North America was the largest region in the metabolic syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in metabolic syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metabolic syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metabolic syndrome market consists of revenues earned by entities by providing services such medical management, nutrition counseling, physical activity programs, and insulin resistance management. The market value includes the value of related goods sold by the service provider or included within the service offering. The metabolic syndrome market also includes sales of risperidone, olanzapine, lithium and valproate, and fluoxetine or sertraline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metabolic Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metabolic syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metabolic syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The metabolic syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Type 1 Metabolic Syndrome; Type 2 Metabolic Syndrome; Type 3 Metabolic Syndrome
• 2) By Risk Factors: Obesity; Insulin Resistance; High Blood Pressure; High Cholesterol
• 3) By Treatment: Medication; Lifestyle Changes; Other Treatments
• 4) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
• 5) By End User: Hospitals; Homecare; Specialty Centres; Other End Users
• Subsegments:
• 1) By Type 1 Metabolic Syndrome: Insulin Resistance Syndrome; Abdominal Obesity Syndrome; Hyperglycemia Syndrome
• 2) By Type 2 Metabolic Syndrome: Elevated Blood Pressure Syndrome; Dyslipidemia Syndrome; Low HDL Cholesterol Syndrome
• 3) By Type 3 Metabolic Syndrome: Atherosclerotic Cardiovascular Disease Syndrome; Non-Alcoholic Fatty Liver Disease Syndrome; Chronic Inflammation Syndrome
• Companies Mentioned: Novo Nordisk A/S; Sanofi S.A.; Boehringer Ingelheim GmbH; Eli Lilly and Company; Merck KGaA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metabolic Syndrome Market Characteristics

3. Metabolic Syndrome Market Trends And Strategies

4. Metabolic Syndrome Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Metabolic Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metabolic Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metabolic Syndrome Market Growth Rate Analysis
• 5.4. Global Metabolic Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metabolic Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metabolic Syndrome Total Addressable Market (TAM)

6. Metabolic Syndrome Market Segmentation

• 6.1. Global Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 Metabolic Syndrome
• Type 2 Metabolic Syndrome
• Type 3 Metabolic Syndrome
• 6.2. Global Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obesity
• Insulin Resistance
• High Blood Pressure
• High Cholesterol
• 6.3. Global Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Medication
• Lifestyle Changes
• Other Treatments
• 6.4. Global Metabolic Syndrome Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.5. Global Metabolic Syndrome Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Centres
• Other End Users
• 6.6. Global Metabolic Syndrome Market, Sub-Segmentation Of Type 1 Metabolic Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin Resistance Syndrome
• Abdominal Obesity Syndrome
• Hyperglycemia Syndrome
• 6.7. Global Metabolic Syndrome Market, Sub-Segmentation Of Type 2 Metabolic Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Elevated Blood Pressure Syndrome
• Dyslipidemia Syndrome
• Low HDL Cholesterol Syndrome
• 6.8. Global Metabolic Syndrome Market, Sub-Segmentation Of Type 3 Metabolic Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atherosclerotic Cardiovascular Disease Syndrome
• Non-Alcoholic Fatty Liver Disease Syndrome
• Chronic Inflammation Syndrome

7. Metabolic Syndrome Market Regional And Country Analysis

• 7.1. Global Metabolic Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metabolic Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metabolic Syndrome Market

• 8.1. Asia-Pacific Metabolic Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metabolic Syndrome Market

• 9.1. China Metabolic Syndrome Market Overview
• 9.2. China Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metabolic Syndrome Market

• 10.1. India Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metabolic Syndrome Market

• 11.1. Japan Metabolic Syndrome Market Overview
• 11.2. Japan Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metabolic Syndrome Market

• 12.1. Australia Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metabolic Syndrome Market

• 13.1. Indonesia Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metabolic Syndrome Market

• 14.1. South Korea Metabolic Syndrome Market Overview
• 14.2. South Korea Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metabolic Syndrome Market

• 15.1. Western Europe Metabolic Syndrome Market Overview
• 15.2. Western Europe Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metabolic Syndrome Market

• 16.1. UK Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metabolic Syndrome Market

• 17.1. Germany Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metabolic Syndrome Market

• 18.1. France Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metabolic Syndrome Market

• 19.1. Italy Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metabolic Syndrome Market

• 20.1. Spain Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metabolic Syndrome Market

• 21.1. Eastern Europe Metabolic Syndrome Market Overview
• 21.2. Eastern Europe Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metabolic Syndrome Market

• 22.1. Russia Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metabolic Syndrome Market

• 23.1. North America Metabolic Syndrome Market Overview
• 23.2. North America Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metabolic Syndrome Market

• 24.1. USA Metabolic Syndrome Market Overview
• 24.2. USA Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metabolic Syndrome Market

• 25.1. Canada Metabolic Syndrome Market Overview
• 25.2. Canada Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metabolic Syndrome Market

• 26.1. South America Metabolic Syndrome Market Overview
• 26.2. South America Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metabolic Syndrome Market

• 27.1. Brazil Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metabolic Syndrome Market

• 28.1. Middle East Metabolic Syndrome Market Overview
• 28.2. Middle East Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metabolic Syndrome Market

• 29.1. Africa Metabolic Syndrome Market Overview
• 29.2. Africa Metabolic Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metabolic Syndrome Market, Segmentation By Risk Factors, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metabolic Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metabolic Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Metabolic Syndrome Market Competitive Landscape
• 30.2. Metabolic Syndrome Market Company Profiles
  • 30.2.1. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Boehringer Ingelheim GmbH Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis

31. Metabolic Syndrome Market Other Major And Innovative Companies

• 31.1. Amgen Inc.
• 31.2. AstraZeneca PLC
• 31.3. Adocia
• 31.4. Biocon Ltd.
• 31.5. Bristol-Myers Squibb Company
• 31.6. Cipla Limited
• 31.7. Herbalife International of America Inc.
• 31.8. Abbott Laboratories
• 31.9. Shaklee Corporation
• 31.10. Johnson & Johnson Private Limited
• 31.11. Medtronic plc
• 31.12. Apollo
• 31.13. WW International Inc.
• 31.14. Jenny Craig
• 31.15. DSM

32. Global Metabolic Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metabolic Syndrome Market

34. Recent Developments In The Metabolic Syndrome Market

35. Metabolic Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Metabolic Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metabolic Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metabolic Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료